{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:15:53Z","timestamp":1758809753508,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ucl.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:40:40Z","timestamp":1574167240000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of Candidates for Salvage Therapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Russell E.N.","family":"Becker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max R.","family":"Kates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ucl.2019.09.004_bib1","first-page":"180","article-title":"Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.004_bib2","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.004_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.004_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/BLC-150015","article-title":"Bacillus calmette-gu\u00e9rin (BCG) treatment failures in non-muscle invasive bladder cancer: What truly constitutes unresponsive disease","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.004_bib5","first-page":"20","article-title":"Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition","volume":"191","author":"Lamm","year":"2014","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.004_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.eururo.2016.03.055","article-title":"Bacillus Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: One size does not fit all","volume":"70","author":"McKiernan","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.004_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/oxfordjournals.aje.a121646","article-title":"Cancer and tuberculosis","volume":"9","author":"Pearl","year":"1929","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.004_bib8","first-page":"581","article-title":"Bacillus Calmette-Gu\u00e9rin (B.C.G.) in prophylactic immunization in children : an analysis and critical review","volume":"18","author":"Petroff","year":"1928","journal-title":"Can Med Assoc J"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2019.09.004_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"issue":"3980","key":"10.1016\/j.ucl.2019.09.004_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.172.3980.271","article-title":"Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis","volume":"172","author":"Zbar","year":"1971","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.004_bib11","first-page":"119","article-title":"Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis","volume":"49","author":"Zbar","year":"1972","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.004_bib12","first-page":"931","article-title":"Bladder cancer immunotherapy","volume":"128","author":"Lamm","year":"1982","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.004_bib13","first-page":"27","article-title":"Experience with Bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"128","author":"Brosman","year":"1982","journal-title":"J\u00a0Urol"},{"issue":"17","key":"10.1016\/j.ucl.2019.09.004_bib14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A\u00a0randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.004_bib15","first-page":"820","article-title":"Two courses of intravesical Bacillus Calmette-Guerin for transitional cell carcinoma of the bladder","volume":"136","author":"Haaff","year":"1986","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.004_bib16","first-page":"1706","article-title":"Defining Bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.004_bib17","first-page":"652","article-title":"Long-term follow up of patients treated with 1 or 2, 6-week courses of intravesical Bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor","volume":"144","author":"Coplen","year":"1990","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.004_bib18","first-page":"935","article-title":"Results of 6 weekly intravesical Bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors","volume":"139","author":"Kavoussi","year":"1988","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.004_bib19","first-page":"220","article-title":"Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.004_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3233\/BLC-150039","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease","volume":"2","author":"Steinberg","year":"2016","journal-title":"Bladder Cancer"},{"issue":"6 Suppl 1","key":"10.1016\/j.ucl.2019.09.004_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of\u00a0stage T1 tumors of the bladder: international consensus panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.004_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options for BCG failures","volume":"24","author":"O'Donnell","year":"2006","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.004_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"year":"2018","series-title":"BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment","key":"10.1016\/j.ucl.2019.09.004_bib24"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.004_bib25","first-page":"2158","article-title":"A\u00a0review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group","volume":"186","author":"Brausi","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"16","key":"10.1016\/j.ucl.2019.09.004_bib26","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.004_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.004_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-018-2438-9","article-title":"ICUD-SIU international consultation on bladder cancer 2017: management of non-muscle invasive bladder cancer","volume":"37","author":"Monteiro","year":"2019","journal-title":"World J Urol"},{"year":"2019","author":"National Comprehensive Cancer Network","series-title":"NCCN clinical practice guidelines in oncology: bladder cancer (version 3.2019)","key":"10.1016\/j.ucl.2019.09.004_bib29"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:38:00Z","timestamp":1758807480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014319300825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0094014319300825"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.004","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Candidates for Salvage Therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}